Zacks.com on MSN19h
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Business Insider2d
Novavax’s Market Share and Pipeline Uncertainties Lead to Sell Rating
Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s underwhelming market share for its COVID ...
Tennessean16d
Moderna, Pfizer or Novavax? How the three Covid-19 vaccines differ according to Yale Medicine
With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...
NBC Connecticut20d
Fact Check: Q&A on the 2024-2025 COVID-19 Vaccines
(The Novavax vaccine works in a similar way to ... Previously, VSD identified a statistical signal for the Pfizer/BioNTech bivalent vaccine in 2022-2023 in people 65 years and older, but numerous ...